Feedback / Questions
lunbotinib (EP0031) - Ellipses Pharma
https://www.prnewswire.com/news-releases/kelun-biotechs-new-drug-application-for-its-novel-next-generation-selective-ret-inhibitor-a400ep0031-accepted-for-review-by-the-nmpa-for-the-treatment-of-ret-fusion-positive-nsclc-302563729.html
Sep 22, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next